nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—BLK—systemic scleroderma	0.426	1	CbGaD
Nilotinib—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0617	0.246	CbGbCtD
Nilotinib—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0345	0.137	CbGbCtD
Nilotinib—ABCG2—Leflunomide—systemic scleroderma	0.0307	0.122	CbGbCtD
Nilotinib—CYP2C8—Mometasone—systemic scleroderma	0.0254	0.101	CbGbCtD
Nilotinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.019	0.0755	CbGbCtD
Nilotinib—ABCB1—Lisinopril—systemic scleroderma	0.0116	0.0462	CbGbCtD
Nilotinib—CYP2C9—Leflunomide—systemic scleroderma	0.0114	0.0454	CbGbCtD
Nilotinib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0101	0.0402	CbGbCtD
Nilotinib—ABCB1—Captopril—systemic scleroderma	0.00869	0.0346	CbGbCtD
Nilotinib—CYP2D6—Captopril—systemic scleroderma	0.00819	0.0326	CbGbCtD
Nilotinib—ABCG2—Methotrexate—systemic scleroderma	0.00761	0.0303	CbGbCtD
Nilotinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00684	0.0272	CbGbCtD
Nilotinib—ABCB1—Prednisone—systemic scleroderma	0.00547	0.0218	CbGbCtD
Nilotinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0041	0.0163	CbGbCtD
Nilotinib—EPHA2—pulmonary artery—systemic scleroderma	0.00348	0.0489	CbGeAlD
Nilotinib—KIT—myenteric nerve plexus—systemic scleroderma	0.00347	0.0488	CbGeAlD
Nilotinib—CYP3A4—Prednisone—systemic scleroderma	0.00328	0.013	CbGbCtD
Nilotinib—CYP2C9—cardial valve—systemic scleroderma	0.00304	0.0429	CbGeAlD
Nilotinib—ABCB1—Methotrexate—systemic scleroderma	0.00274	0.0109	CbGbCtD
Nilotinib—MAPK8—artery—systemic scleroderma	0.00218	0.0307	CbGeAlD
Nilotinib—MAPK8—endothelium—systemic scleroderma	0.00184	0.026	CbGeAlD
Nilotinib—MAPK8—blood vessel—systemic scleroderma	0.0017	0.0239	CbGeAlD
Nilotinib—TIE1—endothelium—systemic scleroderma	0.0016	0.0225	CbGeAlD
Nilotinib—TIE1—blood vessel—systemic scleroderma	0.00147	0.0207	CbGeAlD
Nilotinib—TEK—artery—systemic scleroderma	0.00126	0.0177	CbGeAlD
Nilotinib—EPHB4—endothelium—systemic scleroderma	0.00111	0.0156	CbGeAlD
Nilotinib—MAPK14—blood vessel—systemic scleroderma	0.00108	0.0152	CbGeAlD
Nilotinib—TEK—endothelium—systemic scleroderma	0.00106	0.015	CbGeAlD
Nilotinib—EPHB4—blood vessel—systemic scleroderma	0.00102	0.0144	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Mometasone—systemic scleroderma	0.00101	0.647	CbGdCrCtD
Nilotinib—EPHA2—blood vessel—systemic scleroderma	0.001	0.0141	CbGeAlD
Nilotinib—TEK—blood vessel—systemic scleroderma	0.00098	0.0138	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—systemic scleroderma	0.000882	0.0124	CbGeAlD
Nilotinib—MAPK8—connective tissue—systemic scleroderma	0.000872	0.0123	CbGeAlD
Nilotinib—LYN—connective tissue—systemic scleroderma	0.000804	0.0113	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—systemic scleroderma	0.000797	0.0112	CbGeAlD
Nilotinib—EPHB2—digestive system—systemic scleroderma	0.000788	0.0111	CbGeAlD
Nilotinib—MAPK8—skin of body—systemic scleroderma	0.000787	0.0111	CbGeAlD
Nilotinib—KIT—endothelium—systemic scleroderma	0.000769	0.0108	CbGeAlD
Nilotinib—KIT—blood vessel—systemic scleroderma	0.00071	0.00999	CbGeAlD
Nilotinib—CDC42BPB—digestive system—systemic scleroderma	0.000696	0.0098	CbGeAlD
Nilotinib—PDGFRB—blood vessel—systemic scleroderma	0.000693	0.00975	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—systemic scleroderma	0.000691	0.00973	CbGeAlD
Nilotinib—CDC42BPB—tendon—systemic scleroderma	0.000663	0.00933	CbGeAlD
Nilotinib—MAPK8—digestive system—systemic scleroderma	0.00063	0.00886	CbGeAlD
Nilotinib—MAPK8—tendon—systemic scleroderma	0.000599	0.00843	CbGeAlD
Nilotinib—CA3—connective tissue—systemic scleroderma	0.000593	0.00835	CbGeAlD
Nilotinib—CDC42BPB—lung—systemic scleroderma	0.000581	0.00818	CbGeAlD
Nilotinib—MAPK14—connective tissue—systemic scleroderma	0.000554	0.00779	CbGeAlD
Nilotinib—EPHA3—lung—systemic scleroderma	0.000551	0.00776	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—systemic scleroderma	0.00055	0.353	CbGdCrCtD
Nilotinib—MAP4K1—tendon—systemic scleroderma	0.000545	0.00767	CbGeAlD
Nilotinib—MAPK8—lung—systemic scleroderma	0.000526	0.0074	CbGeAlD
Nilotinib—EPHB4—connective tissue—systemic scleroderma	0.000525	0.00739	CbGeAlD
Nilotinib—EPHB3—digestive system—systemic scleroderma	0.000519	0.00731	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—systemic scleroderma	0.000506	0.00713	CbGeAlD
Nilotinib—TEK—connective tissue—systemic scleroderma	0.000502	0.00707	CbGeAlD
Nilotinib—MAPK14—skin of body—systemic scleroderma	0.0005	0.00704	CbGeAlD
Nilotinib—BRAF—tendon—systemic scleroderma	0.000498	0.00701	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—systemic scleroderma	0.00048	0.00676	CbGeAlD
Nilotinib—MAP4K1—lung—systemic scleroderma	0.000478	0.00673	CbGeAlD
Nilotinib—HCK—digestive system—systemic scleroderma	0.000477	0.00672	CbGeAlD
Nilotinib—CA7—digestive system—systemic scleroderma	0.000467	0.00657	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—systemic scleroderma	0.000459	0.00647	CbGeAlD
Nilotinib—TIE1—lung—systemic scleroderma	0.000456	0.00642	CbGeAlD
Nilotinib—PDGFRA—connective tissue—systemic scleroderma	0.000455	0.00641	CbGeAlD
Nilotinib—HCK—tendon—systemic scleroderma	0.000454	0.00639	CbGeAlD
Nilotinib—ABL2—tendon—systemic scleroderma	0.000451	0.00635	CbGeAlD
Nilotinib—BRAF—lung—systemic scleroderma	0.000437	0.00615	CbGeAlD
Nilotinib—EPHB3—lung—systemic scleroderma	0.000434	0.0061	CbGeAlD
Nilotinib—EPHB6—skin of body—systemic scleroderma	0.000433	0.0061	CbGeAlD
Nilotinib—CA12—connective tissue—systemic scleroderma	0.00042	0.00591	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000416	0.00586	CbGeAlD
Nilotinib—EPHA4—tendon—systemic scleroderma	0.000413	0.00581	CbGeAlD
Nilotinib—CA9—digestive system—systemic scleroderma	0.00041	0.00577	CbGeAlD
Nilotinib—CA3—tendon—systemic scleroderma	0.000408	0.00574	CbGeAlD
Nilotinib—CSF1R—connective tissue—systemic scleroderma	0.000401	0.00564	CbGeAlD
Nilotinib—MAPK14—digestive system—systemic scleroderma	0.0004	0.00563	CbGeAlD
Nilotinib—HCK—lung—systemic scleroderma	0.000398	0.00561	CbGeAlD
Nilotinib—FGR—digestive system—systemic scleroderma	0.000398	0.00561	CbGeAlD
Nilotinib—ABL2—lung—systemic scleroderma	0.000396	0.00557	CbGeAlD
Nilotinib—CA9—tendon—systemic scleroderma	0.00039	0.00549	CbGeAlD
Nilotinib—MAPK14—tendon—systemic scleroderma	0.000381	0.00536	CbGeAlD
Nilotinib—EPHB4—digestive system—systemic scleroderma	0.000379	0.00534	CbGeAlD
Nilotinib—FGR—tendon—systemic scleroderma	0.000379	0.00533	CbGeAlD
Nilotinib—EPHA2—digestive system—systemic scleroderma	0.000372	0.00523	CbGeAlD
Nilotinib—CA14—tendon—systemic scleroderma	0.00037	0.00521	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000366	0.00516	CbGeAlD
Nilotinib—KIT—connective tissue—systemic scleroderma	0.000364	0.00512	CbGeAlD
Nilotinib—EPHA4—lung—systemic scleroderma	0.000362	0.0051	CbGeAlD
Nilotinib—CSF1R—skin of body—systemic scleroderma	0.000362	0.00509	CbGeAlD
Nilotinib—EPHB4—tendon—systemic scleroderma	0.000361	0.00508	CbGeAlD
Nilotinib—CA3—lung—systemic scleroderma	0.000358	0.00504	CbGeAlD
Nilotinib—PDGFRB—connective tissue—systemic scleroderma	0.000355	0.005	CbGeAlD
Nilotinib—EPHA2—tendon—systemic scleroderma	0.000354	0.00498	CbGeAlD
Nilotinib—TEK—tendon—systemic scleroderma	0.000345	0.00486	CbGeAlD
Nilotinib—MAPK14—lung—systemic scleroderma	0.000334	0.0047	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—systemic scleroderma	0.000333	0.00468	CbGeAlD
Nilotinib—LCK—lung—systemic scleroderma	0.000333	0.00468	CbGeAlD
Nilotinib—FGR—lung—systemic scleroderma	0.000333	0.00468	CbGeAlD
Nilotinib—EPHB6—tendon—systemic scleroderma	0.00033	0.00464	CbGeAlD
Nilotinib—PDGFRA—digestive system—systemic scleroderma	0.000329	0.00463	CbGeAlD
Nilotinib—KIT—skin of body—systemic scleroderma	0.000328	0.00462	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000325	0.00457	CbGeAlD
Nilotinib—PDGFRB—skin of body—systemic scleroderma	0.000321	0.00452	CbGeAlD
Nilotinib—ABL1—connective tissue—systemic scleroderma	0.000317	0.00446	CbGeAlD
Nilotinib—EPHB4—lung—systemic scleroderma	0.000317	0.00446	CbGeAlD
Nilotinib—UGT1A1—digestive system—systemic scleroderma	0.000314	0.00441	CbGeAlD
Nilotinib—PDGFRA—tendon—systemic scleroderma	0.000313	0.0044	CbGeAlD
Nilotinib—EPHA2—lung—systemic scleroderma	0.000311	0.00437	CbGeAlD
Nilotinib—CA12—digestive system—systemic scleroderma	0.000303	0.00427	CbGeAlD
Nilotinib—TEK—lung—systemic scleroderma	0.000303	0.00426	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—systemic scleroderma	0.00029	0.00408	CbGeAlD
Nilotinib—EPHB6—lung—systemic scleroderma	0.00029	0.00408	CbGeAlD
Nilotinib—CSF1R—digestive system—systemic scleroderma	0.000289	0.00407	CbGeAlD
Nilotinib—ABL1—skin of body—systemic scleroderma	0.000286	0.00403	CbGeAlD
Nilotinib—MAP2K5—tendon—systemic scleroderma	0.000282	0.00397	CbGeAlD
Nilotinib—CSF1R—tendon—systemic scleroderma	0.000275	0.00388	CbGeAlD
Nilotinib—PDGFRA—lung—systemic scleroderma	0.000274	0.00386	CbGeAlD
Nilotinib—KIT—digestive system—systemic scleroderma	0.000263	0.0037	CbGeAlD
Nilotinib—PDGFRB—digestive system—systemic scleroderma	0.000257	0.00361	CbGeAlD
Nilotinib—CA12—lung—systemic scleroderma	0.000253	0.00357	CbGeAlD
Nilotinib—MAP2K5—lung—systemic scleroderma	0.000248	0.00349	CbGeAlD
Nilotinib—PDGFRB—tendon—systemic scleroderma	0.000244	0.00344	CbGeAlD
Nilotinib—CSF1R—lung—systemic scleroderma	0.000242	0.0034	CbGeAlD
Nilotinib—CA1—digestive system—systemic scleroderma	0.00024	0.00338	CbGeAlD
Nilotinib—ABL1—digestive system—systemic scleroderma	0.000229	0.00322	CbGeAlD
Nilotinib—KIT—lung—systemic scleroderma	0.000219	0.00309	CbGeAlD
Nilotinib—ABL1—tendon—systemic scleroderma	0.000218	0.00306	CbGeAlD
Nilotinib—CA2—connective tissue—systemic scleroderma	0.000216	0.00304	CbGeAlD
Nilotinib—PDGFRB—lung—systemic scleroderma	0.000214	0.00302	CbGeAlD
Nilotinib—CA1—lung—systemic scleroderma	0.000201	0.00282	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—systemic scleroderma	0.000197	0.00278	CbGeAlD
Nilotinib—CA2—skin of body—systemic scleroderma	0.000195	0.00274	CbGeAlD
Nilotinib—ABCB1—blood vessel—systemic scleroderma	0.000192	0.0027	CbGeAlD
Nilotinib—ABL1—lung—systemic scleroderma	0.000191	0.00269	CbGeAlD
Nilotinib—CA4—digestive system—systemic scleroderma	0.000188	0.00264	CbGeAlD
Nilotinib—CA4—tendon—systemic scleroderma	0.000179	0.00252	CbGeAlD
Nilotinib—CYP2B6—skin of body—systemic scleroderma	0.000166	0.00234	CbGeAlD
Nilotinib—CA4—lung—systemic scleroderma	0.000157	0.00221	CbGeAlD
Nilotinib—CA2—digestive system—systemic scleroderma	0.000156	0.00219	CbGeAlD
Nilotinib—CA2—tendon—systemic scleroderma	0.000148	0.00209	CbGeAlD
Nilotinib—CYP2B6—digestive system—systemic scleroderma	0.000133	0.00187	CbGeAlD
Nilotinib—CYP2C9—digestive system—systemic scleroderma	0.000132	0.00185	CbGeAlD
Nilotinib—CA2—lung—systemic scleroderma	0.00013	0.00183	CbGeAlD
Nilotinib—ABCG2—lung—systemic scleroderma	0.00012	0.0017	CbGeAlD
Nilotinib—CYP2B6—lung—systemic scleroderma	0.000111	0.00156	CbGeAlD
Nilotinib—CYP3A4—digestive system—systemic scleroderma	0.0001	0.00141	CbGeAlD
Nilotinib—CYP2D6—digestive system—systemic scleroderma	9.89e-05	0.00139	CbGeAlD
Nilotinib—ABCB1—digestive system—systemic scleroderma	7.11e-05	0.001	CbGeAlD
Nilotinib—Hypertension—Mycophenolate mofetil—systemic scleroderma	5.99e-05	0.000424	CcSEcCtD
Nilotinib—Urticaria—Leflunomide—systemic scleroderma	5.97e-05	0.000423	CcSEcCtD
Nilotinib—Abdominal pain—Leflunomide—systemic scleroderma	5.94e-05	0.000421	CcSEcCtD
Nilotinib—Body temperature increased—Leflunomide—systemic scleroderma	5.94e-05	0.000421	CcSEcCtD
Nilotinib—ABCB1—lung—systemic scleroderma	5.94e-05	0.000836	CbGeAlD
Nilotinib—Acute coronary syndrome—Prednisone—systemic scleroderma	5.93e-05	0.00042	CcSEcCtD
Nilotinib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	5.91e-05	0.000418	CcSEcCtD
Nilotinib—Chest pain—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000418	CcSEcCtD
Nilotinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000418	CcSEcCtD
Nilotinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000418	CcSEcCtD
Nilotinib—Neuropathy peripheral—Prednisone—systemic scleroderma	5.9e-05	0.000417	CcSEcCtD
Nilotinib—Myocardial infarction—Prednisone—systemic scleroderma	5.9e-05	0.000417	CcSEcCtD
Nilotinib—Breast disorder—Methotrexate—systemic scleroderma	5.89e-05	0.000417	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	5.89e-05	0.000416	CcSEcCtD
Nilotinib—Anxiety—Mycophenolate mofetil—systemic scleroderma	5.88e-05	0.000416	CcSEcCtD
Nilotinib—Hypersensitivity—Azathioprine—systemic scleroderma	5.86e-05	0.000415	CcSEcCtD
Nilotinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	5.86e-05	0.000415	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.86e-05	0.000415	CcSEcCtD
Nilotinib—Insomnia—Lisinopril—systemic scleroderma	5.84e-05	0.000413	CcSEcCtD
Nilotinib—Discomfort—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000413	CcSEcCtD
Nilotinib—Paraesthesia—Lisinopril—systemic scleroderma	5.8e-05	0.00041	CcSEcCtD
Nilotinib—Vomiting—Captopril—systemic scleroderma	5.8e-05	0.00041	CcSEcCtD
Nilotinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	5.77e-05	0.000409	CcSEcCtD
Nilotinib—Dyspnoea—Lisinopril—systemic scleroderma	5.76e-05	0.000408	CcSEcCtD
Nilotinib—Rash—Captopril—systemic scleroderma	5.75e-05	0.000407	CcSEcCtD
Nilotinib—Dermatitis—Captopril—systemic scleroderma	5.75e-05	0.000407	CcSEcCtD
Nilotinib—Headache—Captopril—systemic scleroderma	5.71e-05	0.000404	CcSEcCtD
Nilotinib—Confusional state—Mycophenolate mofetil—systemic scleroderma	5.71e-05	0.000404	CcSEcCtD
Nilotinib—Dyspepsia—Lisinopril—systemic scleroderma	5.69e-05	0.000402	CcSEcCtD
Nilotinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	5.67e-05	0.000401	CcSEcCtD
Nilotinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	5.67e-05	0.000401	CcSEcCtD
Nilotinib—Oedema—Mycophenolate mofetil—systemic scleroderma	5.66e-05	0.000401	CcSEcCtD
Nilotinib—Infection—Mycophenolate mofetil—systemic scleroderma	5.62e-05	0.000398	CcSEcCtD
Nilotinib—Decreased appetite—Lisinopril—systemic scleroderma	5.62e-05	0.000397	CcSEcCtD
Nilotinib—Eosinophilia—Methotrexate—systemic scleroderma	5.58e-05	0.000395	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	5.58e-05	0.000395	CcSEcCtD
Nilotinib—Fatigue—Lisinopril—systemic scleroderma	5.57e-05	0.000394	CcSEcCtD
Nilotinib—Shock—Mycophenolate mofetil—systemic scleroderma	5.57e-05	0.000394	CcSEcCtD
Nilotinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	5.55e-05	0.000393	CcSEcCtD
Nilotinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000392	CcSEcCtD
Nilotinib—Hypersensitivity—Leflunomide—systemic scleroderma	5.54e-05	0.000392	CcSEcCtD
Nilotinib—Pancreatitis—Methotrexate—systemic scleroderma	5.53e-05	0.000391	CcSEcCtD
Nilotinib—Constipation—Lisinopril—systemic scleroderma	5.52e-05	0.000391	CcSEcCtD
Nilotinib—Pain—Lisinopril—systemic scleroderma	5.52e-05	0.000391	CcSEcCtD
Nilotinib—Tachycardia—Mycophenolate mofetil—systemic scleroderma	5.52e-05	0.000391	CcSEcCtD
Nilotinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5.5e-05	0.000389	CcSEcCtD
Nilotinib—Bradycardia—Prednisone—systemic scleroderma	5.5e-05	0.000389	CcSEcCtD
Nilotinib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000387	CcSEcCtD
Nilotinib—Diarrhoea—Azathioprine—systemic scleroderma	5.45e-05	0.000385	CcSEcCtD
Nilotinib—Haemoglobin—Prednisone—systemic scleroderma	5.43e-05	0.000384	CcSEcCtD
Nilotinib—Nausea—Captopril—systemic scleroderma	5.42e-05	0.000383	CcSEcCtD
Nilotinib—Abdominal discomfort—Methotrexate—systemic scleroderma	5.41e-05	0.000383	CcSEcCtD
Nilotinib—Haemorrhage—Prednisone—systemic scleroderma	5.4e-05	0.000382	CcSEcCtD
Nilotinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	5.39e-05	0.000382	CcSEcCtD
Nilotinib—Asthenia—Leflunomide—systemic scleroderma	5.39e-05	0.000382	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—systemic scleroderma	5.35e-05	0.000379	CcSEcCtD
Nilotinib—Feeling abnormal—Lisinopril—systemic scleroderma	5.32e-05	0.000377	CcSEcCtD
Nilotinib—Pruritus—Leflunomide—systemic scleroderma	5.32e-05	0.000376	CcSEcCtD
Nilotinib—Connective tissue disorder—Prednisone—systemic scleroderma	5.31e-05	0.000376	CcSEcCtD
Nilotinib—Hypotension—Mycophenolate mofetil—systemic scleroderma	5.29e-05	0.000374	CcSEcCtD
Nilotinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.28e-05	0.000374	CcSEcCtD
Nilotinib—Dysuria—Methotrexate—systemic scleroderma	5.27e-05	0.000373	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—systemic scleroderma	5.27e-05	0.000373	CcSEcCtD
Nilotinib—Dizziness—Azathioprine—systemic scleroderma	5.26e-05	0.000373	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	5.24e-05	0.000371	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—systemic scleroderma	5.19e-05	0.000367	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.16e-05	0.000365	CcSEcCtD
Nilotinib—Photosensitivity reaction—Methotrexate—systemic scleroderma	5.15e-05	0.000364	CcSEcCtD
Nilotinib—Asthenia—Mycophenolic acid—systemic scleroderma	5.15e-05	0.000364	CcSEcCtD
Nilotinib—Diarrhoea—Leflunomide—systemic scleroderma	5.14e-05	0.000364	CcSEcCtD
Nilotinib—Urticaria—Lisinopril—systemic scleroderma	5.13e-05	0.000363	CcSEcCtD
Nilotinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.12e-05	0.000362	CcSEcCtD
Nilotinib—Body temperature increased—Lisinopril—systemic scleroderma	5.11e-05	0.000361	CcSEcCtD
Nilotinib—Abdominal pain—Lisinopril—systemic scleroderma	5.11e-05	0.000361	CcSEcCtD
Nilotinib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	5.08e-05	0.00036	CcSEcCtD
Nilotinib—Pruritus—Mycophenolic acid—systemic scleroderma	5.07e-05	0.000359	CcSEcCtD
Nilotinib—Vomiting—Azathioprine—systemic scleroderma	5.06e-05	0.000358	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—systemic scleroderma	5.06e-05	0.000358	CcSEcCtD
Nilotinib—Eye disorder—Prednisone—systemic scleroderma	5.05e-05	0.000357	CcSEcCtD
Nilotinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000357	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—systemic scleroderma	5.03e-05	0.000356	CcSEcCtD
Nilotinib—Infestation—Methotrexate—systemic scleroderma	5.03e-05	0.000356	CcSEcCtD
Nilotinib—Rash—Azathioprine—systemic scleroderma	5.02e-05	0.000355	CcSEcCtD
Nilotinib—Dermatitis—Azathioprine—systemic scleroderma	5.01e-05	0.000355	CcSEcCtD
Nilotinib—Flushing—Prednisone—systemic scleroderma	5.01e-05	0.000355	CcSEcCtD
Nilotinib—Headache—Azathioprine—systemic scleroderma	4.99e-05	0.000353	CcSEcCtD
Nilotinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.98e-05	0.000353	CcSEcCtD
Nilotinib—Dizziness—Leflunomide—systemic scleroderma	4.97e-05	0.000352	CcSEcCtD
Nilotinib—Renal failure—Methotrexate—systemic scleroderma	4.94e-05	0.00035	CcSEcCtD
Nilotinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.92e-05	0.000348	CcSEcCtD
Nilotinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.91e-05	0.000347	CcSEcCtD
Nilotinib—Stomatitis—Methotrexate—systemic scleroderma	4.9e-05	0.000347	CcSEcCtD
Nilotinib—Angiopathy—Prednisone—systemic scleroderma	4.9e-05	0.000347	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—systemic scleroderma	4.89e-05	0.000346	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.000346	CcSEcCtD
Nilotinib—Immune system disorder—Prednisone—systemic scleroderma	4.88e-05	0.000345	CcSEcCtD
Nilotinib—Constipation—Mycophenolate mofetil—systemic scleroderma	4.84e-05	0.000343	CcSEcCtD
Nilotinib—Pain—Mycophenolate mofetil—systemic scleroderma	4.84e-05	0.000343	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—systemic scleroderma	4.82e-05	0.000341	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—systemic scleroderma	4.79e-05	0.000339	CcSEcCtD
Nilotinib—Vomiting—Leflunomide—systemic scleroderma	4.78e-05	0.000338	CcSEcCtD
Nilotinib—Alopecia—Prednisone—systemic scleroderma	4.77e-05	0.000338	CcSEcCtD
Nilotinib—Hypersensitivity—Lisinopril—systemic scleroderma	4.76e-05	0.000337	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.75e-05	0.000336	CcSEcCtD
Nilotinib—Dizziness—Mycophenolic acid—systemic scleroderma	4.74e-05	0.000336	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—systemic scleroderma	4.74e-05	0.000336	CcSEcCtD
Nilotinib—Rash—Leflunomide—systemic scleroderma	4.74e-05	0.000335	CcSEcCtD
Nilotinib—Dermatitis—Leflunomide—systemic scleroderma	4.74e-05	0.000335	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—systemic scleroderma	4.73e-05	0.000335	CcSEcCtD
Nilotinib—Nausea—Azathioprine—systemic scleroderma	4.73e-05	0.000335	CcSEcCtD
Nilotinib—Headache—Leflunomide—systemic scleroderma	4.71e-05	0.000333	CcSEcCtD
Nilotinib—Erythema—Prednisone—systemic scleroderma	4.7e-05	0.000333	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—systemic scleroderma	4.7e-05	0.000333	CcSEcCtD
Nilotinib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	4.66e-05	0.00033	CcSEcCtD
Nilotinib—Asthenia—Lisinopril—systemic scleroderma	4.63e-05	0.000328	CcSEcCtD
Nilotinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000328	CcSEcCtD
Nilotinib—Pruritus—Lisinopril—systemic scleroderma	4.57e-05	0.000323	CcSEcCtD
Nilotinib—Vomiting—Mycophenolic acid—systemic scleroderma	4.56e-05	0.000323	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—systemic scleroderma	4.54e-05	0.000321	CcSEcCtD
Nilotinib—Rash—Mycophenolic acid—systemic scleroderma	4.52e-05	0.00032	CcSEcCtD
Nilotinib—Dermatitis—Mycophenolic acid—systemic scleroderma	4.52e-05	0.00032	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—systemic scleroderma	4.51e-05	0.000319	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—systemic scleroderma	4.51e-05	0.000319	CcSEcCtD
Nilotinib—Urticaria—Mycophenolate mofetil—systemic scleroderma	4.5e-05	0.000318	CcSEcCtD
Nilotinib—Headache—Mycophenolic acid—systemic scleroderma	4.49e-05	0.000318	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—systemic scleroderma	4.48e-05	0.000317	CcSEcCtD
Nilotinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.47e-05	0.000317	CcSEcCtD
Nilotinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.47e-05	0.000317	CcSEcCtD
Nilotinib—Nausea—Leflunomide—systemic scleroderma	4.47e-05	0.000316	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—systemic scleroderma	4.46e-05	0.000315	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—systemic scleroderma	4.43e-05	0.000314	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—systemic scleroderma	4.42e-05	0.000313	CcSEcCtD
Nilotinib—Diarrhoea—Lisinopril—systemic scleroderma	4.42e-05	0.000313	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—systemic scleroderma	4.36e-05	0.000309	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—systemic scleroderma	4.35e-05	0.000308	CcSEcCtD
Nilotinib—Anaemia—Prednisone—systemic scleroderma	4.34e-05	0.000307	CcSEcCtD
Nilotinib—Dizziness—Lisinopril—systemic scleroderma	4.27e-05	0.000302	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—systemic scleroderma	4.27e-05	0.000302	CcSEcCtD
Nilotinib—Nausea—Mycophenolic acid—systemic scleroderma	4.26e-05	0.000301	CcSEcCtD
Nilotinib—Malaise—Prednisone—systemic scleroderma	4.24e-05	0.0003	CcSEcCtD
Nilotinib—Vertigo—Prednisone—systemic scleroderma	4.22e-05	0.000299	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—systemic scleroderma	4.22e-05	0.000298	CcSEcCtD
Nilotinib—Syncope—Prednisone—systemic scleroderma	4.22e-05	0.000298	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—systemic scleroderma	4.21e-05	0.000298	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—systemic scleroderma	4.19e-05	0.000296	CcSEcCtD
Nilotinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.17e-05	0.000295	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—systemic scleroderma	4.13e-05	0.000292	CcSEcCtD
Nilotinib—Vomiting—Lisinopril—systemic scleroderma	4.11e-05	0.000291	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—systemic scleroderma	4.09e-05	0.00029	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—systemic scleroderma	4.08e-05	0.000288	CcSEcCtD
Nilotinib—Rash—Lisinopril—systemic scleroderma	4.07e-05	0.000288	CcSEcCtD
Nilotinib—Dermatitis—Lisinopril—systemic scleroderma	4.07e-05	0.000288	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—systemic scleroderma	4.07e-05	0.000288	CcSEcCtD
Nilotinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.06e-05	0.000287	CcSEcCtD
Nilotinib—Hypertension—Prednisone—systemic scleroderma	4.06e-05	0.000287	CcSEcCtD
Nilotinib—Chills—Methotrexate—systemic scleroderma	4.05e-05	0.000287	CcSEcCtD
Nilotinib—Headache—Lisinopril—systemic scleroderma	4.05e-05	0.000286	CcSEcCtD
Nilotinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	4e-05	0.000283	CcSEcCtD
Nilotinib—Myalgia—Prednisone—systemic scleroderma	4e-05	0.000283	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—systemic scleroderma	4e-05	0.000283	CcSEcCtD
Nilotinib—Anxiety—Prednisone—systemic scleroderma	3.99e-05	0.000282	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—systemic scleroderma	3.99e-05	0.000282	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.97e-05	0.000281	CcSEcCtD
Nilotinib—Discomfort—Prednisone—systemic scleroderma	3.95e-05	0.00028	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—systemic scleroderma	3.95e-05	0.00028	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—systemic scleroderma	3.93e-05	0.000278	CcSEcCtD
Nilotinib—Erythema—Methotrexate—systemic scleroderma	3.93e-05	0.000278	CcSEcCtD
Nilotinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.87e-05	0.000274	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—systemic scleroderma	3.85e-05	0.000272	CcSEcCtD
Nilotinib—Nausea—Lisinopril—systemic scleroderma	3.84e-05	0.000272	CcSEcCtD
Nilotinib—Oedema—Prednisone—systemic scleroderma	3.84e-05	0.000271	CcSEcCtD
Nilotinib—Infection—Prednisone—systemic scleroderma	3.81e-05	0.00027	CcSEcCtD
Nilotinib—Back pain—Methotrexate—systemic scleroderma	3.8e-05	0.000269	CcSEcCtD
Nilotinib—Shock—Prednisone—systemic scleroderma	3.77e-05	0.000267	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—systemic scleroderma	3.76e-05	0.000266	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—systemic scleroderma	3.74e-05	0.000265	CcSEcCtD
Nilotinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.74e-05	0.000265	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—systemic scleroderma	3.73e-05	0.000264	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—systemic scleroderma	3.71e-05	0.000262	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—systemic scleroderma	3.7e-05	0.000262	CcSEcCtD
Nilotinib—Anorexia—Prednisone—systemic scleroderma	3.66e-05	0.000259	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—systemic scleroderma	3.65e-05	0.000258	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—systemic scleroderma	3.63e-05	0.000257	CcSEcCtD
Nilotinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.6e-05	0.000255	CcSEcCtD
Nilotinib—Rash—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000253	CcSEcCtD
Nilotinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000252	CcSEcCtD
Nilotinib—Headache—Mycophenolate mofetil—systemic scleroderma	3.55e-05	0.000251	CcSEcCtD
Nilotinib—Malaise—Methotrexate—systemic scleroderma	3.54e-05	0.000251	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—systemic scleroderma	3.53e-05	0.00025	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—systemic scleroderma	3.52e-05	0.000249	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.5e-05	0.000247	CcSEcCtD
Nilotinib—Insomnia—Prednisone—systemic scleroderma	3.47e-05	0.000246	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—systemic scleroderma	3.44e-05	0.000244	CcSEcCtD
Nilotinib—Cough—Methotrexate—systemic scleroderma	3.43e-05	0.000243	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—systemic scleroderma	3.38e-05	0.000239	CcSEcCtD
Nilotinib—Nausea—Mycophenolate mofetil—systemic scleroderma	3.36e-05	0.000238	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—systemic scleroderma	3.34e-05	0.000237	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—systemic scleroderma	3.34e-05	0.000237	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—systemic scleroderma	3.34e-05	0.000237	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—systemic scleroderma	3.33e-05	0.000236	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.32e-05	0.000235	CcSEcCtD
Nilotinib—Fatigue—Prednisone—systemic scleroderma	3.31e-05	0.000234	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—systemic scleroderma	3.3e-05	0.000234	CcSEcCtD
Nilotinib—Constipation—Prednisone—systemic scleroderma	3.28e-05	0.000232	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—systemic scleroderma	3.23e-05	0.000229	CcSEcCtD
Nilotinib—Infection—Methotrexate—systemic scleroderma	3.19e-05	0.000225	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—systemic scleroderma	3.16e-05	0.000224	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—systemic scleroderma	3.14e-05	0.000223	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—systemic scleroderma	3.14e-05	0.000222	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—systemic scleroderma	3.14e-05	0.000222	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—systemic scleroderma	3.11e-05	0.00022	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—systemic scleroderma	3.1e-05	0.000219	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—systemic scleroderma	3.06e-05	0.000216	CcSEcCtD
Nilotinib—Urticaria—Prednisone—systemic scleroderma	3.05e-05	0.000216	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—systemic scleroderma	3.03e-05	0.000215	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—systemic scleroderma	3.03e-05	0.000215	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—systemic scleroderma	3e-05	0.000212	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.92e-05	0.000207	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—systemic scleroderma	2.9e-05	0.000205	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—systemic scleroderma	2.88e-05	0.000204	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—systemic scleroderma	2.86e-05	0.000202	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—systemic scleroderma	2.83e-05	0.0002	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—systemic scleroderma	2.82e-05	0.0002	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—systemic scleroderma	2.79e-05	0.000197	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.77e-05	0.000196	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—systemic scleroderma	2.76e-05	0.000196	CcSEcCtD
Nilotinib—Asthenia—Prednisone—systemic scleroderma	2.75e-05	0.000195	CcSEcCtD
Nilotinib—Pain—Methotrexate—systemic scleroderma	2.74e-05	0.000194	CcSEcCtD
Nilotinib—Pruritus—Prednisone—systemic scleroderma	2.71e-05	0.000192	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—systemic scleroderma	2.64e-05	0.000187	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—systemic scleroderma	2.62e-05	0.000186	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.62e-05	0.000186	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—systemic scleroderma	2.55e-05	0.00018	CcSEcCtD
Nilotinib—Dizziness—Prednisone—systemic scleroderma	2.54e-05	0.00018	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—systemic scleroderma	2.53e-05	0.000179	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—systemic scleroderma	2.53e-05	0.000179	CcSEcCtD
Nilotinib—Vomiting—Prednisone—systemic scleroderma	2.44e-05	0.000173	CcSEcCtD
Nilotinib—Rash—Prednisone—systemic scleroderma	2.42e-05	0.000171	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—systemic scleroderma	2.42e-05	0.000171	CcSEcCtD
Nilotinib—Headache—Prednisone—systemic scleroderma	2.4e-05	0.00017	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—systemic scleroderma	2.36e-05	0.000167	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—systemic scleroderma	2.3e-05	0.000163	CcSEcCtD
Nilotinib—Nausea—Prednisone—systemic scleroderma	2.28e-05	0.000161	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—systemic scleroderma	2.27e-05	0.000161	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—systemic scleroderma	2.19e-05	0.000155	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—systemic scleroderma	2.12e-05	0.00015	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—systemic scleroderma	2.04e-05	0.000144	CcSEcCtD
Nilotinib—Rash—Methotrexate—systemic scleroderma	2.02e-05	0.000143	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—systemic scleroderma	2.02e-05	0.000143	CcSEcCtD
Nilotinib—Headache—Methotrexate—systemic scleroderma	2.01e-05	0.000142	CcSEcCtD
Nilotinib—Nausea—Methotrexate—systemic scleroderma	1.9e-05	0.000135	CcSEcCtD
Nilotinib—PDGFRB—Immune System—CD247—systemic scleroderma	1.39e-05	0.000128	CbGpPWpGaD
Nilotinib—CA9—Metabolism—CTGF—systemic scleroderma	1.38e-05	0.000127	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CSK—systemic scleroderma	1.37e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CTLA4—systemic scleroderma	1.37e-05	0.000126	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CSK—systemic scleroderma	1.37e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RHOB—systemic scleroderma	1.37e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—MMP2—systemic scleroderma	1.36e-05	0.000126	CbGpPWpGaD
Nilotinib—LYN—Immune System—IRF8—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—LYN—Immune System—ITGAM—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD247—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SMAD7—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IRF8—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ITGAM—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD247—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.36e-05	0.000125	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RHOB—systemic scleroderma	1.35e-05	0.000125	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD40LG—systemic scleroderma	1.35e-05	0.000124	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IRF5—systemic scleroderma	1.35e-05	0.000124	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1A—systemic scleroderma	1.35e-05	0.000124	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1A—systemic scleroderma	1.35e-05	0.000124	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1A—systemic scleroderma	1.34e-05	0.000124	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD40LG—systemic scleroderma	1.34e-05	0.000123	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD40LG—systemic scleroderma	1.34e-05	0.000123	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD40LG—systemic scleroderma	1.33e-05	0.000123	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SMAD7—systemic scleroderma	1.33e-05	0.000122	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD40LG—systemic scleroderma	1.32e-05	0.000122	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TNFAIP3—systemic scleroderma	1.3e-05	0.00012	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—MMP1—systemic scleroderma	1.3e-05	0.00012	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—MMP1—systemic scleroderma	1.3e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IRF8—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD247—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ITGAM—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HSPG2—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BLK—systemic scleroderma	1.29e-05	0.000119	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD247—systemic scleroderma	1.29e-05	0.000118	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.28e-05	0.000118	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HSPG2—systemic scleroderma	1.28e-05	0.000118	CbGpPWpGaD
Nilotinib—LYN—Immune System—TNFAIP3—systemic scleroderma	1.28e-05	0.000117	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TNFAIP3—systemic scleroderma	1.27e-05	0.000117	CbGpPWpGaD
Nilotinib—LYN—Immune System—BLK—systemic scleroderma	1.26e-05	0.000116	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SMAD7—systemic scleroderma	1.26e-05	0.000116	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BLK—systemic scleroderma	1.26e-05	0.000116	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CSK—systemic scleroderma	1.25e-05	0.000115	CbGpPWpGaD
Nilotinib—KIT—Immune System—CTLA4—systemic scleroderma	1.24e-05	0.000114	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—MMP1—systemic scleroderma	1.23e-05	0.000114	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CSK—systemic scleroderma	1.23e-05	0.000113	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RHOB—systemic scleroderma	1.23e-05	0.000113	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.21e-05	0.000111	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TNFAIP3—systemic scleroderma	1.21e-05	0.000111	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BLK—systemic scleroderma	1.2e-05	0.00011	CbGpPWpGaD
Nilotinib—LCK—Immune System—CSK—systemic scleroderma	1.19e-05	0.000109	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.18e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CTLA4—systemic scleroderma	1.17e-05	0.000108	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRF5—systemic scleroderma	1.17e-05	0.000108	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	1.17e-05	0.000107	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	1.16e-05	0.000107	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	1.15e-05	0.000106	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.15e-05	0.000106	CbGpPWpGaD
Nilotinib—LCK—Disease—HSPG2—systemic scleroderma	1.14e-05	0.000105	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-DQB1—systemic scleroderma	1.13e-05	0.000104	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CSK—systemic scleroderma	1.12e-05	0.000103	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRF8—systemic scleroderma	1.12e-05	0.000103	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD247—systemic scleroderma	1.12e-05	0.000103	CbGpPWpGaD
Nilotinib—LCK—Immune System—ITGAM—systemic scleroderma	1.12e-05	0.000103	CbGpPWpGaD
Nilotinib—CA14—Metabolism—NOS3—systemic scleroderma	1.11e-05	0.000102	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	1.1e-05	0.000101	CbGpPWpGaD
Nilotinib—LCK—Disease—CSK—systemic scleroderma	1.1e-05	0.000101	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	1.09e-05	0.0001	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—HSPG2—systemic scleroderma	1.09e-05	0.0001	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	1.09e-05	9.99e-05	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—MMP9—systemic scleroderma	1.08e-05	9.96e-05	CbGpPWpGaD
Nilotinib—CA6—Metabolism—NOS3—systemic scleroderma	1.08e-05	9.93e-05	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—MMP9—systemic scleroderma	1.08e-05	9.91e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1A—systemic scleroderma	1.07e-05	9.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—CTGF—systemic scleroderma	1.07e-05	9.87e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—MMP1—systemic scleroderma	1.07e-05	9.83e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD40LG—systemic scleroderma	1.07e-05	9.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	1.06e-05	9.78e-05	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	1.06e-05	9.73e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTLA4—systemic scleroderma	1.06e-05	9.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	1.05e-05	9.67e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TNFAIP3—systemic scleroderma	1.05e-05	9.63e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.05e-05	9.62e-05	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TGFB1—systemic scleroderma	1.04e-05	9.55e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BLK—systemic scleroderma	1.03e-05	9.51e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTLA4—systemic scleroderma	1.03e-05	9.51e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD247—systemic scleroderma	1.03e-05	9.49e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RHOB—systemic scleroderma	1.03e-05	9.47e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTLA4—systemic scleroderma	1.03e-05	9.46e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP2—systemic scleroderma	1.03e-05	9.46e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—MMP9—systemic scleroderma	1.03e-05	9.44e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	1.02e-05	9.41e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-DQB1—systemic scleroderma	1.02e-05	9.38e-05	CbGpPWpGaD
Nilotinib—CA7—Metabolism—NOS3—systemic scleroderma	1.01e-05	9.27e-05	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.93e-06	9.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	9.91e-06	9.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTLA4—systemic scleroderma	9.79e-06	9.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RHOB—systemic scleroderma	9.76e-06	8.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP2—systemic scleroderma	9.74e-06	8.96e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.73e-06	8.96e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	9.71e-06	8.93e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1A—systemic scleroderma	9.68e-06	8.91e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	9.64e-06	8.87e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD40LG—systemic scleroderma	9.62e-06	8.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	9.57e-06	8.81e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—NOS3—systemic scleroderma	9.44e-06	8.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—NOS3—systemic scleroderma	9.4e-06	8.65e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CSK—systemic scleroderma	9.37e-06	8.63e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—NOS3—systemic scleroderma	9.34e-06	8.59e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	9.22e-06	8.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HSPG2—systemic scleroderma	9.2e-06	8.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1A—systemic scleroderma	9.16e-06	8.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—systemic scleroderma	9.11e-06	8.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NOS3—systemic scleroderma	8.95e-06	8.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CSK—systemic scleroderma	8.89e-06	8.18e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EDN1—systemic scleroderma	8.76e-06	8.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	8.69e-06	8e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-DQB1—systemic scleroderma	8.51e-06	7.83e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTLA4—systemic scleroderma	8.47e-06	7.79e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	8.47e-06	7.79e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TGFB1—systemic scleroderma	8.46e-06	7.78e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	8.44e-06	7.76e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—NOS3—systemic scleroderma	8.41e-06	7.74e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	8.33e-06	7.66e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1A—systemic scleroderma	8.25e-06	7.59e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CTGF—systemic scleroderma	8.23e-06	7.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—systemic scleroderma	8.21e-06	7.55e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1A—systemic scleroderma	8.08e-06	7.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-DQB1—systemic scleroderma	8.06e-06	7.42e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1A—systemic scleroderma	8.04e-06	7.4e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—systemic scleroderma	8.03e-06	7.39e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—systemic scleroderma	8e-06	7.36e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	7.96e-06	7.32e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.92e-06	7.29e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL1B—systemic scleroderma	7.75e-06	7.13e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NOS3—systemic scleroderma	7.74e-06	7.12e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—systemic scleroderma	7.72e-06	7.11e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	7.69e-06	7.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CSK—systemic scleroderma	7.68e-06	7.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1A—systemic scleroderma	7.66e-06	7.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—systemic scleroderma	7.62e-06	7.01e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—NOS3—systemic scleroderma	7.44e-06	6.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—systemic scleroderma	7.32e-06	6.74e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—NOS3—systemic scleroderma	7.14e-06	6.57e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1B—systemic scleroderma	7.02e-06	6.46e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1B—systemic scleroderma	7.02e-06	6.46e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1B—systemic scleroderma	7e-06	6.44e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CTGF—systemic scleroderma	6.98e-06	6.43e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EDN1—systemic scleroderma	6.98e-06	6.42e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	6.97e-06	6.42e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EDN1—systemic scleroderma	6.91e-06	6.36e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—NOS3—systemic scleroderma	6.84e-06	6.3e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HSPG2—systemic scleroderma	6.76e-06	6.22e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1A—systemic scleroderma	6.62e-06	6.09e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—systemic scleroderma	6.58e-06	6.06e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TGFB1—systemic scleroderma	6.37e-06	5.86e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	6.34e-06	5.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EDN1—systemic scleroderma	6.29e-06	5.79e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TGFB1—systemic scleroderma	6.24e-06	5.75e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	6.22e-06	5.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TGFB1—systemic scleroderma	6.03e-06	5.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS3—systemic scleroderma	6.02e-06	5.54e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—NOS3—systemic scleroderma	6.02e-06	5.54e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCL2—systemic scleroderma	5.99e-06	5.51e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	5.96e-06	5.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TGFB1—systemic scleroderma	5.92e-06	5.45e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.84e-06	5.38e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	5.72e-06	5.26e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	5.69e-06	5.24e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—systemic scleroderma	5.6e-06	5.15e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—TGFB1—systemic scleroderma	5.56e-06	5.12e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS3—systemic scleroderma	5.48e-06	5.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	5.37e-06	4.94e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NOS3—systemic scleroderma	5.34e-06	4.91e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EDN1—systemic scleroderma	5.25e-06	4.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS3—systemic scleroderma	5.18e-06	4.77e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CTGF—systemic scleroderma	5.12e-06	4.71e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—systemic scleroderma	5.12e-06	4.71e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	5.07e-06	4.67e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—systemic scleroderma	5.05e-06	4.64e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	4.98e-06	4.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EDN1—systemic scleroderma	4.98e-06	4.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—systemic scleroderma	4.78e-06	4.4e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCL2—systemic scleroderma	4.77e-06	4.39e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCL2—systemic scleroderma	4.73e-06	4.35e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	4.7e-06	4.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS3—systemic scleroderma	4.67e-06	4.3e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	4.65e-06	4.28e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CTGF—systemic scleroderma	4.33e-06	3.99e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	4.31e-06	3.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—systemic scleroderma	4.3e-06	3.96e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL2—systemic scleroderma	4.3e-06	3.96e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—systemic scleroderma	4.28e-06	3.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—systemic scleroderma	4.25e-06	3.91e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—systemic scleroderma	4.21e-06	3.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—systemic scleroderma	4.21e-06	3.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—systemic scleroderma	4.19e-06	3.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	4.07e-06	3.75e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	4.07e-06	3.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—systemic scleroderma	3.99e-06	3.68e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—systemic scleroderma	3.98e-06	3.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—systemic scleroderma	3.83e-06	3.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CTGF—systemic scleroderma	3.78e-06	3.48e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—systemic scleroderma	3.75e-06	3.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	3.67e-06	3.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	3.63e-06	3.34e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—systemic scleroderma	3.62e-06	3.33e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—systemic scleroderma	3.59e-06	3.31e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—systemic scleroderma	3.58e-06	3.3e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CTGF—systemic scleroderma	3.56e-06	3.27e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—systemic scleroderma	3.53e-06	3.25e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CTGF—systemic scleroderma	3.53e-06	3.25e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—systemic scleroderma	3.45e-06	3.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—systemic scleroderma	3.43e-06	3.15e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—systemic scleroderma	3.41e-06	3.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—systemic scleroderma	3.41e-06	3.13e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—systemic scleroderma	3.38e-06	3.11e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	3.36e-06	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	3.27e-06	3.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—systemic scleroderma	3.2e-06	2.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—systemic scleroderma	3.09e-06	2.84e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—systemic scleroderma	3.08e-06	2.83e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.07e-06	2.83e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—systemic scleroderma	3.04e-06	2.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—systemic scleroderma	3.04e-06	2.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	2.94e-06	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	2.91e-06	2.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—systemic scleroderma	2.81e-06	2.59e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—systemic scleroderma	2.79e-06	2.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	2.62e-06	2.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	2.62e-06	2.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—systemic scleroderma	2.57e-06	2.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	2.54e-06	2.33e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—systemic scleroderma	2.48e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—systemic scleroderma	2.44e-06	2.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	2.4e-06	2.21e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.33e-06	2.14e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—systemic scleroderma	2.23e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	2.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	2.12e-06	1.95e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	2.11e-06	1.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—systemic scleroderma	2.01e-06	1.85e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.89e-06	1.74e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	1.74e-06	1.6e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—systemic scleroderma	1.64e-06	1.51e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.55e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.54e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.01e-06	9.32e-06	CbGpPWpGaD
